GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (NAS:VERU) » Definitions » Sloan Ratio %

Veru (VERU) Sloan Ratio %

: 0.00% (As of Dec. 2023)
View and export this data going back to 1990. Start your Free Trial

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Veru's Sloan Ratio for the quarter that ended in Dec. 2023 was 0.00%.

As of Dec. 2023, Veru has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Veru Sloan Ratio % Historical Data

The historical data trend for Veru's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Sloan Ratio %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.98 -32.86 4.68 -30.14 -22.94

Veru Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.14 -68.07 -41.82 -26.66 -

Competitive Comparison

For the Biotechnology subindustry, Veru's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veru Sloan Ratio % Distribution

For the Biotechnology industry and Healthcare sector, Veru's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Veru's Sloan Ratio % falls into.



Veru Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Veru's Sloan Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Sloan Ratio=(Net Income (A: Sep. 2023 )-Cash Flow from Operations (A: Sep. 2023 )
-Cash Flow from Investing (A: Sep. 2023 ))/Total Assets (A: Sep. 2023 )
=(-93.153--88.014
-6.334)/50.023
=-22.94%

Veru's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-64.586--59.5
-6.619)/80.567
=-14.53%

Veru's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -38.793 (Mar. 2023 ) + -6.66 (Jun. 2023 ) + -10.857 (Sep. 2023 ) + -8.276 (Dec. 2023 ) = $-64.59 Mil.
Veru's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -25.556 (Mar. 2023 ) + -18.432 (Jun. 2023 ) + -9.492 (Sep. 2023 ) + -6.02 (Dec. 2023 ) = $-59.50 Mil.
Veru's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -0.142 (Mar. 2023 ) + 5.974 (Jun. 2023 ) + 0.787 (Sep. 2023 ) + 0 (Dec. 2023 ) = $6.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Veru  (NAS:VERU) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Veru has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Veru Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Veru's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Veru (VERU) Business Description

Traded in Other Exchanges
Address
2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
Executives
Mario Eisenberger director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Harry Fisch director, 10 percent owner 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Grace Hyun director 48 NW 25TH STREET, SUITE 102, MIAMI FL 33127
Mitchell Shuster Steiner director, 10 percent owner, officer: President and CEO 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
K Gary Barnette officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michele Greco officer: VP and CFO 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60654
Jesus Socorro director 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Todd Charles T Jr officer: CEO of FHC Division 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michael L Rankowitz director 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Robert Getzenberg officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elgar Peerschke director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Daniel Haines officer: CFO and COO 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
David R Bethune director THE FEMALE HEALTH COMPANY, 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60610
O B Parrish director, officer: Chairman/Chief Exec. Officer

Veru (VERU) Headlines

From GuruFocus

Veru to Present at the Jefferies Healthcare Conference

By sperokesalga sperokesalga 05-24-2023